The Latest Analyst Ratings for Lumos Pharma
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish and somewhat bullish ratings for Lumos Pharma (NASDAQ:LUMO) in the last quarter. According to 5 analysts offering 12-month price targets in the last 3 months, Lumos Pharma has an average price target of $19.4, which has increased by 21.25% over the past month.
August 15, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have provided bullish ratings for Lumos Pharma, with an average price target of $19.4, which has increased by 21.25% over the past month.
The bullish ratings and increased price target indicate a positive outlook for Lumos Pharma. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100